Funded by the Food and Drug Administration, the Rare Disease Cures Accelerator-Data and Analytics Platform (RDCA-DAP) has just been launched. The resource is intended to accelerate rare disease research. Approved investigators will have access to deidentified patient-level data. “RDCA-DAP […]
RWE Informs Decision-Making for Vaccines, Digital Therapeutics, and Medications
Real world evidence (RWE) is increasingly used in healthcare and pharma decision-making. A recent article explores its use in addressing questions related to COVID-19 vaccines, digital therapeutics, and medications. Tracking patient outcomes is critical in understanding the impact of these products […]
Recent ISPOR Study Highlights the Use of RWE in Decision-Making
In a recent study published in Value in Health, researchers investigated how real world evidence (RWE) impacted decision-making by the European Medicines Agency. RWE was especially useful in assessing adverse events and tracking patient outcomes. The authors remark, “Ensuring transparency of RWE […]
HealthVerity Waterfall Strategy Uses Open and Closed De-Identified RWD to Understand COVID-19 and Emerging Variants
Real world data (RWD) has already yielded remarkable insight throughout the COVID-19 pandemic. One data management strategy uses both open and closed claims data to understand the overall impact of COVID-19 and its variants. Open claims are often derived from lab results and medical claims while […]
IQVIA Announces New Partnership With HealthCore to Expedite RWE Studies
IQVIA has announced a new partnership with real world research leader HealthCore. Together, the two organizations will promote real world evidence (RWE) studies. The collaboration is expected to improve data analysis and will in part focus on the use of de-identified real world data (RWD) from […]
HealthEconomics.Com Announces Results of 2021 Insight Survey on Value Communication
HealthEconomics.Com, a Scientist.com company, reported the findings of its 2021 Insight Survey on Value Communication in Pharma HEOR, RWE & Market Access. More than 200 professionals were surveyed to understand the impact of value communication in health economics and outcomes research (HEOR) […]
ICER’s RWE Study of Hereditary Angioedema Treatments Provides New Insight
The Institute for Clinical and Economic Review (ICER) recently published results from a real world evidence study (RWE) assessing the efficacy and cost-effectiveness of three drugs used in cases of hereditary angioedema (HAE). The study provided a unique perspective and ICER noted an updated pricing […]
Massive Bio Announces Partnership With Patient-Centered Group Self Care Catalysts and Veterans Prostate Cancer Awareness Non-Profit to Improve Clinical Trial Diversity and Oncology RWE
Massive Bio will partner with non-profit group Veterans Prostate Cancer Awareness (VPCa) and patient-centered organization Self-Care Catalysts to promote enrollment in clinical trials and in real world evidence (RWE) studies. Massive Bio provides extensive experience in clinical trial enrollment […]
IMPACT HTA Issues Recommendations on RWE in Decision-Making, Highlights Transparency
IMPACT Health Technology Assessment (HTA) has issued a series of recommendations intended to inform decision-makers using real world evidence (RWE). The guidelines address existing challenges and gaps ahead of recommendations issued by the Food and Drug Administration and the UK’s National Institute […]
NESTcc to Add Multi-Disciplinary Stakeholders to RWD Healthcare Group
The Medical Device Innovation Consortium (MDIC)’s National Evaluation System for health Technology Coordinating Center (NESTcc) issued a call for experts to serve in its Active Surveillance Data Curation Working Group. Applicants will be notified on September 17th, 2021. “The Active Surveillance […]
